CAPSULAR POLYSACCHARIDE REGULATES NEUTROPHIL COMPLEMENT RECEPTOR INTERACTIONS WITH TYPE-III GROUP-B STREPTOCOCCI

被引:26
作者
EDWARDS, MS
WESSELS, MR
BAKER, CJ
机构
[1] HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115
[2] HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV INFECT DIS,BOSTON,MA 02215
关键词
D O I
10.1128/IAI.61.7.2866-2871.1993
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The capsular polysaccharide of type III group B streptococci contributes substantially to the virulence of this organism. We explored the extent to which capsular polysaccharide influences neutrophil complement receptor interactions by using a poorly encapsulated strain (COH 31r/s), two well-encapsulated strains (M732 and M912), and strains produced from COH 31r/s by transposon mutagenesis that lacked capsule (COH 31-15) or had capsular polysaccharide lacking terminal sialic acid residues (COH 31-21). When tested with normal human serum, each strain had initially high bactericidal indices (85 to 96%). Monoclonal antibody blockade of neutrophil complement receptor 3 (CD11b/CD18) inhibited opsonophagocytosis to a significantly greater extent for the well-encapsulated strain than for the poorly encapsulated, asialo, or unencapsulated mutant strain. The addition of antibody with specificity for capsular polysaccharide reduced the inhibitory effect significantly for the encapsulated but not for the mutant strains. Blockade of neutrophil complement receptor 1 (CD35) effected only low-level inhibition. However, simultaneous blockade of complement receptors 1 and 3 augmented the inhibitory effect. When hypogammaglobulinemic serum was used as an antibody-free complement source, the initial bactericidal index was low (30% +/- 15%) for an encapsulated strain and was not affected for the mutant strains. Blockade of either neutrophil complement receptor 1 or 3 or the combination fully inhibited killing of the encapsulated strain. These results demonstrate that the type III group B streptococcal capsular polysaccharide regulates interactions with neutrophil complement receptors. We conclude that efficient phagocytic killing of encapsulated group streptococci in nonimmune serum requires ligation of complement receptors 1 and 3.
引用
收藏
页码:2866 / 2871
页数:6
相关论文
共 33 条
[1]   ABNORMAL MOBILITY OF NEONATAL POLYMORPHONUCLEAR LEUKOCYTES - RELATIONSHIP TO IMPAIRED REDISTRIBUTION OF SURFACE-ADHESION SITES BY CHEMOTACTIC FACTOR OR COLCHICINE [J].
ANDERSON, DC ;
HUGHES, BJ ;
SMITH, CW .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (04) :863-874
[2]   THE SEVERE AND MODERATE PHENOTYPES OF HERITABLE MAC-1, LFA-1 DEFICIENCY - THEIR QUANTITATIVE DEFINITION AND RELATION TO LEUKOCYTE DYSFUNCTION AND CLINICAL-FEATURES [J].
ANDERSON, DC ;
SCHMALSTEIG, FC ;
FINEGOLD, MJ ;
HUGHES, BJ ;
ROTHLEIN, R ;
MILLER, LJ ;
KOHL, S ;
TOSI, MF ;
JACOBS, RL ;
WALDROP, TC ;
GOLDMAN, AS ;
SHEARER, WT ;
SPRINGER, TA .
JOURNAL OF INFECTIOUS DISEASES, 1985, 152 (04) :668-689
[3]   IMMUNOCHEMICAL CHARACTERIZATION OF NATIVE TYPE-3 POLYSACCHARIDE OF GROUP-B STREPTOCOCCUS [J].
BAKER, CJ ;
KASPER, DL ;
DAVIS, CE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1976, 143 (02) :258-270
[4]   INFLUENCE OF PRE-IMMUNIZATION ANTIBODY-LEVELS ON THE SPECIFICITY OF THE IMMUNE-RESPONSE TO RELATED POLYSACCHARIDE ANTIGENS [J].
BAKER, CJ ;
KASPER, DL ;
EDWARDS, MS ;
SCHIFFMAN, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (04) :173-178
[5]   COMPLEMENT RECEPTOR EXPRESSION ON NEUTROPHILS AT AN INFLAMMATORY SITE, THE PSEUDOMONAS-INFECTED LUNG IN CYSTIC-FIBROSIS [J].
BERGER, M ;
SORENSEN, RU ;
TOSI, MF ;
DEARBORN, DG ;
DORING, G .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (04) :1302-1313
[6]  
BJORNSON AB, 1990, REV INFECT DIS, V12, pS161
[7]   LOCALIZATION OF COMPLEMENT COMPONENT-3 ON STREPTOCOCCUS-PNEUMONIAE - ANTI-CAPSULAR ANTIBODY CAUSES COMPLEMENT DEPOSITION ON THE PNEUMOCOCCAL CAPSULE [J].
BROWN, EJ ;
JOINER, KA ;
COLE, RM ;
BERGER, M .
INFECTION AND IMMUNITY, 1983, 39 (01) :403-409
[8]   DEPOSITION AND DEGRADATION OF C3 ON TYPE-III GROUP-B STREPTOCOCCI [J].
CAMPBELL, JR ;
BAKER, CJ ;
EDWARDS, MS .
INFECTION AND IMMUNITY, 1991, 59 (06) :1978-1983
[9]  
DANA N, 1986, J IMMUNOL, V137, P3259
[10]  
EDWARDS MS, 1982, J IMMUNOL, V128, P1278